The estimated Net Worth of Lambert Shiu is at least $4.35 Million dollars as of 9 October 2023. Mr Shiu owns over 2,750 units of Penumbra Inc stock worth over $3,938,166 and over the last 5 years he sold PEN stock worth over $0. In addition, he makes $413,209 as Chief Accounting Officer at Penumbra Inc.
Mr has made over 2 trades of the Penumbra Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,750 units of PEN stock worth $33,990 on 9 October 2023.
The largest trade he's ever made was exercising 2,750 units of Penumbra Inc stock on 9 October 2023 worth over $33,990. On average, Mr trades about 365 units every 38 days since 2020. As of 9 October 2023 he still owns at least 19,466 units of Penumbra Inc stock.
You can see the complete history of Mr Shiu stock trades at the bottom of the page.
Lambert Shiu is the Chief Accounting Officer at Penumbra Inc.
As the Chief Accounting Officer of Penumbra Inc, the total compensation of Mr Shiu at Penumbra Inc is $413,209. There are 8 executives at Penumbra Inc getting paid more, with Johanna Roberts having the highest compensation of $2,556,370.
Mr Shiu is 41, he's been the Chief Accounting Officer of Penumbra Inc since . There are 15 older and 2 younger executives at Penumbra Inc. The oldest executive at Penumbra Inc is Don Kassing, 78, who is the Presiding Independent Director.
Lambert's mailing address filed with the SEC is ONE PENUMBRA PLACE, , ALAMEDA, CA, 94502.
Over the last 9 years, insiders at Penumbra Inc have traded over $197,637,326 worth of Penumbra Inc stock and bought 700 units worth $109,480 . The most active insiders traders include Adam Elsesser, Arani Bose, and James Robert Pray. On average, Penumbra Inc executives and independent directors trade stock every 9 days with the average trade being worth of $2,030,383. The most recent stock trade was executed by Harpreet Grewal on 4 September 2024, trading 782 units of PEN stock currently worth $159,614.
penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.
Penumbra Inc executives and other stock owners filed with the SEC include: